Abstract
Background: Contrast-induced nephropathy (CIN) causes the third most hospital-related acute renal damage. Flexible percutaneous coronary intervention (PCI) is risky. CIN can occur in almost 50% of PCI patients. As this consequence increases patient morbidity and mortality beyond PCI. Thus, early CIN risk detection and prediction are essential to patient care. CHA2DS2-VASc, a simple risk assessment tool, can complement the more advanced CIN risk score model.
Objective: To a find out the association between CHA2DS2-VASc score and contrast induced nephropathy after percutaneous coronary intervention in patients with chronic coronary syndromes.
Methods: This cross-sectional observational study was conducted at the Department of Cardiology at National Institute of Cardiovascular Diseases (NICVD), Dhaka during the period from May, 2020 to April, 2021. A total 100 patients with chronic coronary syndromes undergoing PCI were enrolled in this study. CHA2DS2- VASc score was calculated for each patient. These patients were divided into two groups as Group I (score < 4) and Group II (score ≥ 4). After PCI was done, patients were followed up to see development of contrast induced nephropathy. CIN was defined as increase in serum creatinine level (≥ 0.5mg/dl) or relative increase (≥25%) increase from baseline within 24 to 48 hours after PCI.
Results: The mean ±SD CHA2DS2-VASc score was 3.23 ± 1.14. Most of the subjects (41 out of 100) belonged to 51-60 years’ age group. Males were prevalent than females. No significant difference was noted regarding history of dyslipidaemia, smoking, family history of CAD between group I and group II except for DM, hypertension and lower ejection fraction. DM and hypertension were more frequent in group II than group I (28 % vs 56%, p=0.005) and (40 % vs 54%, p= 0.04) respectively. LVEF was lower in group II than group I (54.621% vs 48.06%, p = 0.001). Both pre and post catheterization serum creatinine were significantly higher in group II compared to group I. CIN was significantly higher in group I (16%) than group II (24%). In multivariate analysis demonstrated CHA2DS2- VASc score of ≥4 to be an independent predictor of contrast induced nephropathy (CIN).
Conclusion: In patients with chronic coronary syndromes undergoing percutaneous coronary intervention CHA2DS2-VASc score may be used as a novel, simple, and a sensitive diagnostic tool for the prediction of contrast induced nephropathy (CIN).
Full text
Read the article in your browser with search, text selection and highlighting, open it full screen, or download the PDF.